CN113896915B - Gel material and preparation method and application thereof - Google Patents
Gel material and preparation method and application thereof Download PDFInfo
- Publication number
- CN113896915B CN113896915B CN202111326226.7A CN202111326226A CN113896915B CN 113896915 B CN113896915 B CN 113896915B CN 202111326226 A CN202111326226 A CN 202111326226A CN 113896915 B CN113896915 B CN 113896915B
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- crosslinking
- site
- gel
- spermidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract description 281
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 247
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 247
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 246
- 238000004132 cross linking Methods 0.000 claims abstract description 190
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract description 168
- 229940063673 spermidine Drugs 0.000 claims abstract description 140
- 238000006243 chemical reaction Methods 0.000 claims abstract description 129
- 229940063675 spermine Drugs 0.000 claims abstract description 84
- 229920000768 polyamine Polymers 0.000 claims abstract description 68
- 230000001954 sterilising effect Effects 0.000 claims abstract description 43
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 42
- 238000011049 filling Methods 0.000 claims abstract description 19
- 239000000499 gel Substances 0.000 claims description 215
- 239000000243 solution Substances 0.000 claims description 73
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 62
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000017 hydrogel Substances 0.000 claims description 37
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 36
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 32
- 239000012190 activator Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 238000010298 pulverizing process Methods 0.000 claims description 28
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- -1 1, 3-bis [ bis (methoxymethyl) methyl ] carbodiimide Chemical compound 0.000 claims description 23
- 125000005626 carbonium group Chemical group 0.000 claims description 21
- 239000008055 phosphate buffer solution Substances 0.000 claims description 21
- 125000003277 amino group Chemical group 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 239000011259 mixed solution Substances 0.000 claims description 12
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 claims description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 150000004714 phosphonium salts Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 25
- 230000015556 catabolic process Effects 0.000 abstract description 13
- 210000004872 soft tissue Anatomy 0.000 abstract description 8
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 239000002244 precipitate Substances 0.000 description 37
- 239000007863 gel particle Substances 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000007821 HATU Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000008213 purified water Substances 0.000 description 20
- 229920002385 Sodium hyaluronate Polymers 0.000 description 19
- 239000003431 cross linking reagent Substances 0.000 description 19
- 229940010747 sodium hyaluronate Drugs 0.000 description 19
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- 238000004090 dissolution Methods 0.000 description 18
- 239000012467 final product Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 229940071643 prefilled syringe Drugs 0.000 description 15
- 238000001291 vacuum drying Methods 0.000 description 15
- 238000007789 sealing Methods 0.000 description 13
- 238000004140 cleaning Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001766 physiological effect Effects 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000005700 Putrescine Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- SKCJYQMVKYFTGQ-UHFFFAOYSA-N 1-hydroxypyrrolidine-2,5-dione;pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1.ON1C(=O)CCC1=O SKCJYQMVKYFTGQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- XXSZPXKCXCZEHZ-UHFFFAOYSA-N 3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;methanediimine;hydrochloride Chemical compound Cl.N=C=N.CCN=C=NCCCN(C)C XXSZPXKCXCZEHZ-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- HTZOOZJNQMCWSV-UHFFFAOYSA-N BrC1C(=O)NC(C1)=O.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound BrC1C(=O)NC(C1)=O.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1 HTZOOZJNQMCWSV-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/17—Amines; Quaternary ammonium compounds
Abstract
The invention provides a gel material, a preparation method and application thereof. The gel material is obtained by crosslinking endogenous polyamine and hyaluronic acid, wherein the endogenous polyamine comprises spermine and/or spermidine; crosslinking of endogenous polyamines with hyaluronic acid includes two-site crosslinking, three-site crosslinking or four-site crosslinking. The invention influences various properties of the gel and the degradation release speed of polyamine by controlling the reaction crosslinking site. After the gel is subjected to damp-heat sterilization, the loss rate of elastic modulus is low, the rheological property of the gel before sterilization can be effectively maintained, the thermal stability of the hyaluronic acid gel is greatly improved, and the usability of the gel in the fields of soft tissue filling, soft tissue repair, medical cosmetology and the like is also improved.
Description
Technical Field
The invention relates to the technical field of biomedical materials, in particular to a gel material and a preparation method and application thereof.
Background
Hyaluronic acid or sodium Hyaluronate (HA) is a disaccharide unit glycosaminoglycan composed of D-glucuronic acid and N-acetylglucosamine through β -1,4 glycosidic bond and β -1,3 glycosidic bond. Widely used in the cosmetic field or ophthalmic surgery, and can also be used as a soft tissue filling agent for repairing wrinkles and some soft tissue defects. Hyaluronic acid is an in-vivo protoplasm, has good biocompatibility and certain biological activity, but exogenous hyaluronic acid can be subjected to degradation of hyaluronidase in vivo to shorten in-vivo residence time, so that the treatment effect is shortened, and the treatment effect can be achieved by multiple injections. In order to avoid degradation of hyaluronic acid by hyaluronidase, the hyaluronic acid molecules are required to be crosslinked through a chemical crosslinking agent to form a space network structure, the degradation of the hyaluronic acid by the hyaluronidase and the like is prevented through a dense rigid network structure, the stay time of exogenous hyaluronic acid in a body is prolonged, and the biocompatibility is ensured and meanwhile, the therapeutic effect is good.
Crosslinking agents for crosslinking hyaluronic acid in the current market are mainly classified into two types, one of which is a bisepoxy crosslinking agent, mainly 1, 4-butanediol diglycidyl ether (BDDE), and the other of which is an unsaturated sulfone crosslinking agent, mainly divinyl sulfone (DVS). The mechanism of the two crosslinking agents is similar, and the basic catalyst is used as a leading condition to catalyze the hydroxyl (-OH) in the hyaluronic acid to carry out addition reaction with the crosslinking agent to complete the crosslinking, wherein the-OH in the hyaluronic acid and BDDE carry out ring-opening addition reaction to complete the crosslinking, and the DVS and the-OH in the hyaluronic acid carry out Michael addition reaction to complete the crosslinking. However, both types of crosslinking agents have a relatively high biotoxicity, while unreacted monomers or crosslinking reaction byproducts also present this potential carcinogenicity. Because hyaluronic acid gel is a long-term implanted medical device product, there is also a lack of long-term data tracking of sufficient sample size in clinical terms to demonstrate the biosafety of the product. In the current market demand, extending the residence time of hyaluronic acid gel in vivo and increasing the viscoelastic properties of hyaluronic acid gel are all major trends in the current industry. The current method for effectively prolonging the in-vivo residence time of the hyaluronic acid gel is to increase the crosslinking degree, and meanwhile, the increase of the crosslinking degree can bring the increase of the viscoelasticity, but under the condition of using the traditional BDDE or DVS crosslinking agent, the worry of people on the safety of the products can be increased by increasing the adding amount of the crosslinking agent.
On this premise, the choice of non-toxic cross-linking agents to make hyaluronic acid gels will also be more sought after by more manufacturers of hyaluronic acid gels worldwide. Currently, nontoxic amino acid crosslinking agents have been used in hyaluronic acid gels, and chinese patent CN10105713211 once discloses crosslinked sodium hyaluronate gels prepared with 4- (4, 6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride as a condensing agent, lysine and its derivatives or arginine and its derivatives as crosslinking agents. Chinese patents CN106188609, CN106188584, CN111732741 disclose crosslinked sodium hyaluronate gels prepared by using 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride carbodiimide as a condensing agent, N-hydroxysuccinimide succinimide as a catalyst, arginine and its derivatives, lysine and its derivatives (including polylysine) as crosslinking agents. The above patents all disclose sodium hyaluronate gel prepared by using a double amino acid such as lysine or arginine as a cross-linking agent. Taking lysine or arginine as an example, the crosslinked hyaluronic acid hydrogel exhibits a large difference in performance upon wet heat sterilization. Of these, CN106188609, CN106188584 and CN111732741 did not show that cross-linked hyaluronic acid could be subjected to wet heat sterilization at 121 ℃ for 15 minutes. Lysine crosslinked hyaluronic acid gel capable of wet heat sterilization is disclosed in CN10105713211, but according to the information disclosed in the patent, the minimum degradation rate of the gel after wet heat sterilization is more than 40%, which indicates that the wet heat sterilization resistance of the gel is poor. The crosslinking reaction of spermine or spermidine with hyaluronic acid is disclosed in US9907739B2, but the gel disclosed in the patent is only a two-site crosslinking, and does not involve multi-site crosslinking, namely, the crosslinking site is only an amino group in spermine or spermidine, the imino group does not participate in the reaction, and the elastic modulus loss rate of the gel after wet heat sterilization is up to 23%, which also indicates that the wet heat sterilization performance of the gel is poor. In addition, the use of hexamethylenediamine crosslinked hyaluronic acid hydrogel is disclosed in the Xang Mei Yan et al (Journal of Biomaterials Applications,2011,27 (2): 179-186), but the elastic modulus of the gel also decreases by more than 20% after sterilization. The main reason is that only two amino crosslinking sites exist in such diamine molecules as lysine, arginine, hexamethylenediamine and the like, and when crosslinking occurs, an amide bond is formed with carboxyl in hyaluronic acid to complete crosslinking, but because the crosslinking sites in the molecule are fewer, the formed crosslinked network structure cannot provide enough thermal stability protection for a hyaluronic acid main chain, and the amide bond has poor thermal stability, so that the gel has higher degradation rate after wet heat sterilization and poor thermal stability.
Endogenous polyamines refer to polyamines that can be synthesized or produced during metabolism in the human environment, and the main endogenous polyamines include spermine, spermidine, putrescine, and the like. Literature (Madeo et al, science 359,410,2018) reports that endogenous polyamines, spermidine, have specific physiological effects including, but not limited to, regulating circadian rhythms, improving hypertension, protecting the cardiovascular system, preventing senile dementia, enhancing immunity, anti-cancer, even anti-aging, and the like. The physiologically active effects of spermidine are represented in the following ways: 1) Kidney: reducing tension and preventing aging; 2) And (3) heart: lowering blood pressure and preventing arteriosclerosis; 3) Brain: preventing memory deterioration, resisting senile dementia, and protecting nerves; 4) Bone: preventing bone loss affected by ovariectomy; 5) Skeletal muscle: raising the temperature of the aged muscles, preventing muscle diseases; 6) Whole organism: prolonging the life of organisms; 7) The immune system: improving immunity after vaccination, improving directional immunity of cancer, and preventing fatal sepsis; 8) Liver: preventing hepatic fibrosis and canceration, etc. The main mechanism of spermidine production physiological activity is represented by: spermidine is polycation (-NH3+) aliphatic amine, exists in a multi-protonizing form under the physiological pH condition, has strong biological activity, contains nucleic acid with acid residues, phospholipid, acidic protein, carboxyl or sulfate containing pectic polysaccharide and neurotransmitters and hormones (such as dopamine, epinephrine, serotonin, thyroid hormone and the like) with similar structures, and can be the target of binding of the spermidine. In terms of binding to nucleic acids, most polyamines exist in the form of polyamine-RNA complexes within cells, with the primary role of spermidine being related to structural changes in RNA and translation, such as by affecting the secondary structure of mRNA, tRNA and rRNA to affect various stages of protein synthesis. Spermidine also forms a stable bridge before the double helix DNA strand, reducing accessibility of ROS or other DNA damaging agents, protecting DNA from thermal denaturation and X-ray radiation. In terms of binding to proteins, spermidine is able to bind to a large number of negatively charged proteins, altering the spatial conformation of the protein, thus affecting its physiological function. Such as protein kinases/phosphatases (an important link in a variety of signaling pathways), enzymes involved in histone methylation and acetylation (by altering epigenetic influence on gene expression), ion channel receptors (e.g., AMPA, AMDA receptors), and the like.
At present, few reports have been made on endogenous polyamines such as spermidine as a crosslinking agent for hyaluronic acid gel, and few reports have been made on the crosslinking reaction conditions between endogenous polyamines and hyaluronic acid and the properties of crosslinked hydrogels, and the present invention has been made in view of this.
Disclosure of Invention
The invention aims to provide a gel material, and a preparation method and application thereof. The preparation method can control the crosslinking sites of endogenous polyamine and hyaluronic acid, influences various performance parameters of the prepared crosslinked hyaluronic acid gel by controlling the crosslinking reaction sites, controls the release speed of endogenous polyamine such as spermidine in the degradation process of the hyaluronic acid gel, and continuously plays the physiological activity role of endogenous polyamine such as spermidine.
The technical scheme provided by the invention is as follows:
in one aspect, the present invention provides a gel material derived primarily from crosslinking endogenous polyamines with hyaluronic acid, the endogenous polyamines including spermine (tetramino compounds) and/or spermidine (triamino compounds); crosslinking of the endogenous polyamine with the hyaluronic acid comprises two-site crosslinking, three-site crosslinking, or four-site crosslinking. In particular, the invention realizes that the endogenous polyamine and the hyaluronic acid are crosslinked at three sites or four sites for the first time to form a multi-site crosslinked active star-shaped network structure.
According to the invention, spermine or spermidine of endogenous polyamine is selected as a multi-site crosslinking agent to form a compact network structure, so that the thermal stability of the formed amide bond crosslinked hyaluronic acid gel is increased. The reason why endogenous diamine such as putrescine is not selected to be used in the invention is that diamine such as putrescine has higher toxicity, and the crosslinking site is the same as amino acid such as lysine and arginine, so that the possibility of realizing multi-site crosslinking is not provided.
In one embodiment, the present invention provides a gel material obtained by crosslinking an endogenous polyamine with hyaluronic acid, the endogenous polyamine comprising spermine and/or spermidine; crosslinking of the endogenous polyamine with the hyaluronic acid comprises two-site crosslinking, three-site crosslinking, or four-site crosslinking.
Further, the amino residue in the gel obtained by the two-site crosslinking is lower than 20%; preferably, the amino residue in the gel obtained by crosslinking in the two-site crosslinking is less than 15%; more preferably, the amino residue in the gel obtained by crosslinking in the double sites accounts for less than 10 percent.
Furthermore, the residual quantity of amino groups and imino groups in the gel obtained by the three-site crosslinking or the four-site crosslinking is lower than 20 percent.
Furthermore, the amino residue in the gel obtained by crosslinking in the three-site crosslinking or four-site crosslinking is less than 15%; preferably, the amino residue in the gel obtained by crosslinking in the three-site crosslinking or four-site crosslinking accounts for less than 10 percent.
Furthermore, the imino residue in the gel obtained by crosslinking in the three-site crosslinking or four-site crosslinking is lower than 15%; preferably, the imino residue in the gel obtained by crosslinking in the three-site crosslinking or four-site crosslinking is less than 10%.
Further, the crosslinking reaction efficiency of the double-site crosslinking, the three-site crosslinking or the four-site crosslinking in the crosslinking reaction of the endogenous polyamine and the hyaluronic acid is higher than 75%; preferably, the crosslinking reaction efficiency is higher than 80%; more preferably, the crosslinking reaction efficiency is higher than 85%.
Further, the elastic modulus loss rate (G' loss rate) of the gel obtained by the crosslinking is lower than 22%; preferably, the modulus of elasticity loss (G' loss) is less than 15%; more preferably, the modulus of elasticity loss ratio (G' loss ratio) is less than 10%.
In another aspect, the present invention provides a method of preparing a gel material, the method comprising the steps of:
Adjusting the pH=4.50-6.50 of a mixed solution of hyaluronic acid and endogenous polyamine, and adding an activating agent to enable the hyaluronic acid and the endogenous polyamine to generate double-site, three-site or four-site crosslinking reaction to obtain the gel material;
wherein the endogenous polyamine comprises spermine and/or spermidine.
The spermidine and spermine have amino groups and imino groups; wherein spermidine contains one imino group and two amino groups, and spermine contains two amino groups and two imino groups. The invention discovers that the reaction sites of spermine or spermidine and hyaluronic acid can be controlled by adjusting the pH value of the mixed solution of hyaluronic acid and endogenous polyamine after dissolution, and double-site crosslinked hydrogel and three-site or four-site crosslinked active star-shaped network gel can be obtained. During the reaction, the amino site reaction of spermine or spermidine (i.e., the two-site reaction) or the amino group and imino group may be co-reacted (i.e., the multi-site reaction) may be adjusted by the pH of the solution. The double-site crosslinking refers to that when hyaluronic acid is crosslinked with spermine or spermidine, amino groups in the spermine or spermidine are taken as main reaction sites, and particularly, the amino residue in gel obtained by the double-site crosslinking is less than 20%; the three-site or four-site crosslinking means that amino and imino in spermine or spermidine are taken together as reaction sites when hyaluronic acid is crosslinked with spermine or spermidine, and particularly, the residual quantity of amino and imino in gel obtained by the three-site crosslinking or four-site crosslinking is less than 20 percent.
The invention discovers that the reaction activity of imino can be improved by controlling the pH value of the solution to be between 5.00 and 5.49, and three-site or four-site reaction can be relatively stably realized; the pH value of the solution is controlled between 4.50 and 4.99 or between 5.50 and 6.50, which can provide imino reaction activity and relatively stably realize the joint participation of multiple sites in the reaction, thus preparing the active star-shaped network gel. Therefore, the invention obtains hyaluronic acid hydrogel taking imino groups as crosslinking sites for the first time, and discovers that hydrogels with different crosslinking sites can obtain different gel properties under the condition of the same crosslinking degree.
In the present invention, controlling the pH of the mixed solution between 5.00 and 5.49, including but not limited to 5.00, 5.10, 5.20, 5.30, 5.40 or 5.49, allows for a relatively stable three-or four-site reaction. Controlling the pH of the mixed solution between 4.50 and 4.99 or 5.50 and 6.50, including but not limited to 4.50, 4.60, 4.70, 4.80, 4.90, 4.99, 5.50, 5.60, 5.70, 5.80, 5.90, 6.00, 6.10, 6.20, 6.30, 6.40 or 6.50, allows a two-site cross-linking reaction to be achieved relatively stably. The experimental results are not ideal outside the pH defined by the present invention, and the pH range of the present invention is a pH condition suitable for the method of the present invention, which is found through a great number of experiments.
The method is a multi-site active reaction technology (Spermidine/Spermine Multisite Active Reaction Technology, short SMART) of endogenous polyamines (spermine and Spermidine). The method can control the crosslinking site of endogenous polyamine and hyaluronic acid, and further influence various performance parameters of crosslinked hyaluronic acid gel by controlling the crosslinking reaction site. In addition, the release rate of endogenous polyamines such as spermidine in the degradation process of hyaluronic acid gel can be controlled, and the physiological activity of endogenous polyamines such as spermidine can be continuously exerted.
In one embodiment, an activator is added during the two-site crosslinking reaction, three-site crosslinking reaction, or four-site crosslinking reaction;
preferably, the activator comprises one or more of water-soluble carbodiimides, phosphonium bromide salts of triphenylphosphine with bromide, carbonium salts, and 4- (4, 6-dimethoxytriazin-2-yl) -4-methylmorpholine hydrochloride (DMTMM).
In one embodiment, the water-soluble carbodiimide activator includes 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC), 1- (3-dimethylaminopropyl) -3-ethyl-carbodiimide, 1-cyclohexyl-3- (2-morpholinoethyl) carbodiimide, 1, 3-bis [ bis (methoxymethyl) methyl ] carbodiimide, and the like, or salts thereof, and mixtures of one or more thereof.
In one embodiment, the phosphonium bromide salt of triphenylphosphine with bromide includes phosphonium salts of triphenylphosphine with carbon tetrabromide, phosphonium salts of triphenylphosphine with N-bromosuccinimide, and the like. The phosphonium bromide salt is obtained by known methods from triphenylphosphine and bromide in methylene chloride.
In one embodiment, the carbonium salt comprises one or a mixture of several of O- (7-azabenzotriazol-1-yl) -bis (dimethylamino) carbonium Hexafluorophosphate (HATU), O- (benzotriazol-1-yl) -bis (dimethylamino) carbonium Hexafluorophosphate (HBTU), O- (5-chlorobenzotriazol-1-yl) -bis (dimethylamino) carbonium Hexafluorophosphate (HCTU), O- (benzotriazol-1-yl) -bis (dimethylamino) carbonium tetrafluoroborate (TBTU), O- (N-succinimidyl) -bis (dimethylamino) carbonium tetrafluoroborate (TSTU), 2- (5-norbornene-2, 3-dicarboximido) -1, 3-tetramethyluronium tetrafluoroborate (TNTU).
Among the activators, when a water-soluble carbodiimide activator is used, it is necessary to use it simultaneously in combination with an auxiliary agent to improve the crosslinking reaction efficiency. Preferably, the adjuvant comprises any one or more of N-hydroxysuccinimide (NHS), sulphonated N-hydroxysuccinimide (sulpho-NHS), t-butanol, 1-hydroxybenzotriazole (HOBt); more preferably, the adjuvant is added in an amount of 10 to 30% of the mass of the carbodiimide, including but not limited to 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29% and 30%. The water-soluble carbodiimide and the auxiliary agent are combined to ensure that the crosslinking reaction efficiency can reach about 70 percent.
Among three types of activators, namely phosphonium bromide salt, carbonium salt and 4- (4, 6-dimethoxy triazine-2-yl) -4-methylmorpholine hydrochloride, formed by triphenylphosphine and bromide, the highest crosslinking efficiency of the carbonium salt is 80-95%, wherein when HATU catalyst is adopted, the crosslinking efficiency is as high as 95%; the crosslinking efficiency of phosphonium bromide and DMTMM is inferior, and the crosslinking efficiency is in the range of 70-85%.
In a preferred embodiment, HATU of a carbonium salt is used as reaction activator. The molecular formula structure of HATU is shown below (1):
the mechanism by which HATU participates in the amide condensation reaction is as follows:
in the crosslinking reaction, when double-site crosslinking is carried out (the main reaction site of spermine or spermidine is amino), the addition amount of the activator is 200-280% of the amount of the endogenous polyamine substance; including but not limited to 210%, 220%, 230%, 240%, 250%, 260%, 270%, and 280%; when three-site and/or four-site crosslinking is performed (imino sites also participate in the reaction), the activator is added in an amount of 300 to 550% of the amount of the endogenous polyamine species; including but not limited to 320%, 350%, 370%, 390%, 400%, 420%, 450%, 470%, 500%, 520% and 550%, preferably, when the endogenous polyamine is spermine, the activator is added in an amount of 400 to 550% of the amount of the spermine substance, and when the endogenous polyamine is spermidine, the activator is added in an amount of 300 to 400% of the amount of the spermidine substance.
The amount of the activator added is related to the amino crosslinking site of the crosslinking agent spermine or spermidine, and when the activator is used, each molecule of the activator can activate one carboxyl group and carry out an amide coupling reaction with one amino (or imino).
In one embodiment, in the crosslinking reaction, when the endogenous polyamine is spermine, the spermine is added in an amount of 0.3-35% of the mass of the hyaluronic acid, including but not limited to 0.4%, 0.5%, 0.8%, 1%, 3%, 5%, 8%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% and 35%; when the endogenous polyamine is spermidine, the adding amount of the spermidine accounts for 0.5-40% of the mass of the hyaluronic acid; including but not limited to 0.5%, 0.8%, 1%, 3%, 5%, 8%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 34%, 38%, and 40%.
Further, the mass concentration of hyaluronic acid in the aqueous reaction system solution is 10-150 mg/mL, including, for example, but not limited to, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150mg/mL.
Further, in the finally obtained crosslinked hyaluronic acid hydrogel, the mass concentration of hyaluronic acid is 1-50mg/mL, including but not limited to 1, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50mg/mL.
In one embodiment, the hyaluronic acid has a molecular weight of 100KDa (kilodaltons) to 3000KDa; preferably, the hyaluronic acid is hyaluronic acid prepared by a microbial fermentation method.
In one embodiment, in the crosslinking reaction, when the activator comprises a phosphonium bromide salt of a carbonium salt and/or triphenylphosphine with bromide, the temperature of the crosslinking reaction is 10 to 60 ℃ and the time of the crosslinking reaction is 14 to 24 hours;
when the activator comprises water-soluble carbodiimide and/or 4- (4, 6-dimethoxy triazine-2-yl) -4-methylmorpholine hydrochloride, the temperature of the crosslinking reaction is 40-60 ℃, and the time of the crosslinking reaction is 14-24 h.
In the reaction process, the double-site crosslinked gel and the three-site or four-site crosslinked active star-shaped network gel can be controlled by different reaction temperatures and the proportion of the activator and spermine or spermidine. Because the imino is influenced by steric hindrance effect, the reactivity of the imino is lower than that of the primary amino, and therefore, when only the primary amino participates in the double-site reaction, the crosslinking reaction can be completed only by lower temperature and lower addition amount of an activating agent; however, when the imino group is required to participate in the reaction, it is necessary to raise the reaction temperature and to lengthen the reaction time in order to raise the crosslinking reaction efficiency of the imino group in order to increase the reactivity of the imino group.
The crosslinking reaction of spermidine with hyaluronic acid and Spermine with hyaluronic acid is shown below, wherein (3) is the crosslinking reaction of hyaluronic acid with Spermine (specmine) (4-site star network). (4) Is a cross-linking reaction (3-site star network) of hyaluronic acid with Spermidine (spearmine).
The invention adopts the SMART multi-site active reaction technology to prepare the hyaluronic acid gel, fully utilizes the different activities of amino and imino in spermine or spermidine molecules, and can respectively obtain the two-site cross-linked gel and the three-site or four-site cross-linked active star-shaped network gel by controlling one or more of reaction conditions such as pH, temperature, type of active agent and addition amount.
In one embodiment, the gel material is further subjected to an eluent elution, crushing, drying treatment;
preferably, the eluent is an organic solvent; more preferably, the organic solvent is a soluble alcohol or a soluble ketone; more preferably, the organic solvent is ethanol or acetone;
further, the volume ratio of gel to eluent in the reaction system during crushing is 1:1 to 5;
further, the particle size of the gel after pulverization is 10 to 500. Mu.m.
In one embodiment, the method of preparation further comprises re-dissolving, wet heat sterilizing the dried gel material;
Preferably, the reconstituted solution is a phosphate buffered solution; more preferably, the mass concentration of phosphate buffer salt in the phosphate buffer solution is 5-40 mg/mL;
further, the temperature of the wet heat sterilization is 120-130 ℃, and the time of the wet heat sterilization is preferably 15-45 min.
In a specific embodiment, the gel is eluted with an organic solvent and the gel particles are crushed, and the washing may be repeated a plurality of times to remove the residual activator. The drying can be vacuum drying, and the drying can remove the organic solvent. The dissolution efficiency of the residual activator in the multiple cleaning process can be ensured by crushing the gel into a lower particle size.
In a specific embodiment, the gel particles after vacuum drying are reconstituted with phosphate buffer solution, filled into pre-filled syringes and subjected to wet heat sterilization to obtain the final product gel. The pH value of the phosphate buffer solution ranges from 6.8 to 7.6. The concentration of the hyaluronic acid gel of the final product is 1-35 mg/mL.
In a specific embodiment, the method comprises the steps of:
(a) Directly dissolving hyaluronic acid and endogenous polyamine in water, and regulating the pH value of the solution;
(b) Adding an activating agent to complete the crosslinking reaction of spermidine and/or spermine and hyaluronic acid;
(c) Adding an organic eluting agent, crushing gel particles, washing for multiple times to remove residual activating agent, and drying in vacuum to remove organic solvent;
(d) And re-dissolving the gel particles after vacuum drying by using a phosphate buffer solution, filling the re-dissolved gel particles in a pre-filling and sealing syringe, and carrying out damp-heat sterilization to obtain the final product gel.
After the hyaluronic acid gel prepared by the method is subjected to wet heat sterilization, the loss rate of the elastic modulus is low, the minimum loss rate can be controlled within 10%, the rheological property of the gel before sterilization can be effectively maintained, and the thermal stability of the hyaluronic acid gel is improved to a great extent.
The invention designs polyamine such as spermidine as a hyaluronic acid cross-linking agent, and simultaneously takes the whole hyaluronic acid gel as a slow-release gel of polyamine such as spermidine, namely the gel can continuously and prototypically release polyamine substances such as spermidine in the natural degradation process in vivo. The three-site or four-site active star network gel can stably release spermidine monomers under the enzymatic initiation of hyaluronidase, and continuously plays a role in bioactivity of spermidine.
The invention also provides the gel material obtained by the preparation method.
In another aspect, the invention also provides the use of the gel material or the gel material prepared by the preparation method in preparing a tissue filling and repair material or a drug carrier. For example, in the preparation of products for pharmaceutical, medical cosmetic and cosmetic applications, such as soft tissue filling, soft tissue repair, or cosmetic injection for eliminating facial skin wrinkles, etc.
The beneficial effects are that:
(1) The gel material provided by the invention realizes multi-site crosslinking of endogenous polyamine and hyaluronic acid, and forms a more compact network structure;
(2) After the obtained hyaluronic acid gel is subjected to wet heat sterilization, the loss rate of elastic modulus is low (the minimum elastic modulus can be controlled within 10 percent), the rheological property of the gel before sterilization can be effectively maintained, and the thermal stability of the hyaluronic acid gel is greatly improved;
(3) The preparation method can realize the control of the number of crosslinking reaction sites, and further can influence the performance of the prepared crosslinked hyaluronic acid gel;
(4) The invention can control the release rate of endogenous polyamines such as spermidine in the degradation process of hyaluronic acid gel, and continuously exert the physiological activity of endogenous polyamines such as spermidine;
(5) The invention improves the usability of the gel in the fields of soft tissue filling, soft tissue repair, medical cosmetology and the like, and is suitable for popularization and application.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the spermidine cross-linked hyaluronic acid of the present invention 1 H NMR spectrum;
FIG. 2 is a schematic diagram showing cell proliferation of spermidine cross-linked hyaluronic acid provided by the invention;
FIG. 3 is a graph showing the release amount of spermidine from spermidine crosslinked hyaluronic acid gel according to the thermal degradation condition provided by the present invention;
FIG. 4 is a graph showing the release of spermidine from spermidine crosslinked hyaluronic acid gel according to the present invention under enzymatic conditions.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in connection with the embodiments, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1: preparation of double-site crosslinked hydrogel of HATU catalytic spermine and hyaluronic acid
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.03g (mole number: 0.15 mmol) of spermine was added to the hyaluronic acid solution, at this time the spermine content was 1% of the mass of hyaluronic acid (mole number of repeating structural units of hyaluronic acid: 2%). The pH value of the hyaluronic acid solution is regulated to about 6.20 by using a hydrochloric acid solution with the concentration of 6mol/L, then the hyaluronic acid solution is added and stirred uniformly, 0.32mmol of HATU and 213 percent of spermine mol are added, the mixture is stirred uniformly continuously, and the mixture is placed in a constant temperature oven with the temperature of 25 ℃ for reaction for 24 hours in a sealing way. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 158 μm and D0.9 was 196. Mu.m.
Example 2: preparation of three-site crosslinked hydrogel of HATU catalytic spermidine and hyaluronic acid
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.022g (molar number: 0.15 mmol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 0.7% of the mass of hyaluronic acid (molar number of repeating structural units of hyaluronic acid: 2%). Adding 0.48mmol of HATU, namely 320 percent of spermidine mole number, uniformly stirring, adjusting the pH value of the hyaluronic acid solution to about 5.40 by using a 6mol/L hydrochloric acid solution, then adding and uniformly stirring, and sealing and placing into a 50 ℃ incubator for reaction for 14h. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 143. Mu.m, and D0.9 was 201. Mu.m.
Example 3: preparation of four-site crosslinked hydrogel of HATU catalytic spermine and hyaluronic acid
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.03g (mole number: 0.15 mmol) of spermine was added to the hyaluronic acid solution, at this time the spermine content was 1% of the mass of hyaluronic acid (mole number of repeating structural units of hyaluronic acid: 2%). Adding 0.65mmol HATU and 433% of spermine mole number, stirring, adjusting pH of hyaluronic acid solution to about 5.30 with 6mol/L hydrochloric acid solution, stirring, sealing, and reacting in a 60 deg.C incubator for 14h. After the reaction, 40mL of acetone is added, and the gel particles are crushed by an IKAT25 high shear dispersing machine, wherein the crushing speed is 10000 revolutions per minute, and the crushing lasts for 5min. After the completion of the pulverization, 200mL of acetone was further added to completely dehydrate the gel. The precipitate was separated, washed successively with 200mL of acetone for 5 times, and then placed in a vacuum oven and dried under vacuum at 40℃for 24 hours at a vacuum of-0.09 MPa. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 139. Mu.m, and D0.9 was 186. Mu.m.
Example 4: preparation of double-site crosslinked hydrogel of spermidine and hyaluronic acid catalyzed by succinic imide triphenyl phosphonium bromide
Dissolving 0.2mol of triphenylphosphine and 0.2mol of N-bromosuccinimide in 1000mL of dichloromethane, stirring for 24h at 20-25 ℃, removing the dichloromethane by using a rotary evaporator after the reaction is finished to obtain bromosuccinimide triphenyl phosphonium salt, and sealing for later use.
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.022g (molar number: 0.15 mmol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 0.7% of the mass of hyaluronic acid (molar number of repeating structural units of hyaluronic acid: 2%). Adding 0.32mmol of the succinic imide triphenyl phosphonium bromide obtained in the previous step, namely 213 percent of spermidine mole number, uniformly stirring, adjusting the pH value of the hyaluronic acid solution to about 6.00 by using a 6mol/L hydrochloric acid solution, then adding and uniformly stirring, sealing and placing into a constant temperature oven at25 ℃ for reaction for 24 hours. After the reaction, 40mL of acetone is added, and the gel particles are crushed by an IKAT25 high shear dispersing machine, wherein the crushing speed is 10000 revolutions per minute, and the crushing lasts for 5min. After the completion of the pulverization, 200mL of acetone was further added to completely dehydrate the gel. The precipitate was separated, washed successively with 200mL of acetone for 5 times, and then placed in a vacuum oven and dried under vacuum at 40℃for 24 hours at a vacuum of-0.09 MPa. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 141 μm and D0.9 was 191. Mu.m.
Example 5: preparation of three-site crosslinked hydrogel of spermidine and hyaluronic acid catalyzed by succinic imide triphenyl phosphonium bromide
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.022g (molar number: 0.15 mmol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 0.7% of the mass of hyaluronic acid (molar number of repeating structural units of hyaluronic acid: 2%). 0.48mmol of the triphenylphosphonium bromide which is prepared according to the method in the example 4, namely 320 percent of spermidine mole number, is added, the mixture is stirred uniformly, the pH value of the hyaluronic acid solution is regulated to about 5.20 by using a hydrochloric acid solution with the concentration of 6mol/L, then the mixture is added, stirred uniformly, and the mixture is sealed and placed into a constant temperature box with the temperature of 40 ℃ for reaction for 24 hours. After the reaction, 40mL of acetone is added, and the gel particles are crushed by an IKAT25 high shear dispersing machine, wherein the crushing speed is 10000 revolutions per minute, and the crushing lasts for 5min. After the completion of the pulverization, 200mL of acetone was further added to completely dehydrate the gel. The precipitate was separated, washed successively with 200mL of acetone for 5 times, and then placed in a vacuum oven and dried under vacuum at 40℃for 24 hours at a vacuum of-0.09 MPa. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 133. Mu.m, and D0.9 was 178. Mu.m.
Example 6: preparation of DMTMM catalyzed three-site crosslinked hydrogel of spermidine and hyaluronic acid
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.022g (molar number: 0.15 mmol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 0.7% of the mass of hyaluronic acid (molar number of repeating structural units of hyaluronic acid: 2%). Adding DMTMM 0.48mmol, namely 320 percent of spermidine mole number, uniformly stirring, adjusting the pH value of the hyaluronic acid solution to about 5.10 by using a hydrochloric acid solution with the concentration of 6mol/L, then adding the hyaluronic acid solution, uniformly stirring, sealing and placing the hyaluronic acid solution into a constant temperature box with the temperature of 40 ℃ for reaction for 24 hours. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 144. Mu.m, and D0.9 was 206. Mu.m.
Example 7: preparation of four-site crosslinked hydrogel of EDC catalytic spermine and hyaluronic acid
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.03g (mole number: 0.15 mmol) of spermine was added to the hyaluronic acid solution, at this time the spermine content was 1% of the mass of hyaluronic acid (mole number of repeating structural units of hyaluronic acid: 2%). Adding 0.65mmol of EDC, 433% of spermine mole number, adding 20% of NHS of EDC mass, stirring uniformly, regulating pH value of hyaluronic acid solution to about 5.45 with 6mol/L hydrochloric acid solution, stirring uniformly continuously, sealing and placing into a 60 ℃ constant temperature oven for reaction for 14h. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 125. Mu.m, and D0.9 was 193. Mu.m.
Example 8: preparation of multi-site crosslinked hydrogel by combining HATU catalytic spermidine and spermine and participating in hyaluronic acid
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time, the concentration of hyaluronic acid was 30mg/mL, 0.022g (mole number: 0.15 mmol) of spermidine and 0.03g (mole number: 0.15 mmol) of spermine were added to the hyaluronic acid solution, respectively, at this time, the content of spermidine or spermine each accounted for 2% of the mole number of repeating structural units of hyaluronic acid. Adding 0.48mmol of HATU, namely 320 percent of spermidine mole number, adding 0.65mmol of HATU, namely 433 percent of spermine mole number, uniformly stirring, adjusting the pH value of the hyaluronic acid solution to about 5.00 by using a 6mol/L hydrochloric acid solution, then adding and uniformly stirring, sealing and placing into a 50 ℃ incubator for reaction for 14h. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 134. Mu.m, and D0.9 was 236. Mu.m.
Example 9: EDC catalyzes three-site crosslinking of spermidine and hyaluronic acid
6g of sodium hyaluronate (molecular weight 120 kDa) was weighed, then 35mL of purified water was added thereto, and after complete dissolution, at this time the concentration of hyaluronic acid was 150mg/mL, 2.4g (molar number 16.6 mmol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 40% of the mass of hyaluronic acid. Under the precondition of three-site crosslinking, the pH value of the hyaluronic acid solution is regulated to about 5.2 by using a 6mol/L hydrochloric acid solution, then the mixture is added and stirred uniformly, 66.4mmol EDC (that is 400% of the mole number of spermidine) is added, 2.4g of Sulfo-NHS (20% of the mass of EDC) is added at the same time, the mixture is stirred uniformly continuously, and the mixture is sealed and placed into a blast drying box at 60 ℃ for reaction for 24 hours. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. After complete drying, 1.0g of xerogel is taken, 20mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL is added, after the gel is completely swelled, the gel is filled into a prefilled syringe, and moist heat sterilization is carried out at 121 ℃ for 15min, thus obtaining the final product gel. The gel particle diameter D0.5 was 145. Mu.m, and D0.9 was 213. Mu.m.
Example 10: preparation of four-site crosslinked hydrogel of HATU catalytic spermine and hyaluronic acid
0.5g of sodium hyaluronate (molecular weight 2800 kDa) was weighed, then 38.5mL of purified water was added, and after complete dissolution, the concentration of hyaluronic acid was 13.3mg/mL, and 1.5mg (mole number: 7.4. Mu. Mol) of spermine was added to the hyaluronic acid solution, wherein the content of spermine was 0.3% of the mass of hyaluronic acid. On the premise of four-site crosslinking, the pH value of the hyaluronic acid solution is regulated to about 5.2 by using a 6mol/L hydrochloric acid solution, then the hyaluronic acid solution is added and stirred uniformly, 29.6 mu mol of HATU, namely 400% of spermine mole number, is added, and the mixture is continuously stirred uniformly, and is sealed and placed into a blast drying oven at 30 ℃ for reaction for 24 hours. After the reaction, 40mL of acetone is added, and the gel particles are crushed by an IKA T25 high shear disperser, wherein the crushing speed is 10000 revolutions per minute, and the crushing lasts for 5min. After the completion of the pulverization, 200mL of acetone was further added to completely dehydrate the gel. The precipitate was separated, washed successively with 200mL of acetone for 5 times, and then placed in a vacuum oven and dried under vacuum at 40℃for 24 hours at a vacuum of-0.09 MPa. After complete drying, taking 0.4g of xerogel, adding 400mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 156. Mu.m, and D0.9 was 231. Mu.m.
Example 11: preparation of three-site crosslinked hydrogel of HATU catalytic spermidine and hyaluronic acid
0.5g of sodium hyaluronate (molecular weight 2800 kDa) was weighed, then 38.5mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 13.3mg/mL, 2.5mg (molar number: 17.2. Mu. Mol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 0.5% of the mass of hyaluronic acid. On the premise of three-site crosslinking, the pH value of the hyaluronic acid solution is regulated to about 5.2 by using a 6mol/L hydrochloric acid solution, then the hyaluronic acid solution is added and stirred uniformly, 51.6 mu mol of HATU, namely 300% of the mole number of spermidine, is added, and the mixture is continuously stirred uniformly, sealed and placed into a blast drying oven at 30 ℃ for reaction for 24 hours. After the reaction, 40mL of acetone is added, and the gel particles are crushed by an IKAT25 high shear dispersing machine, wherein the crushing speed is 10000 revolutions per minute, and the crushing lasts for 5min. After the completion of the pulverization, 200mL of acetone was further added to completely dehydrate the gel. The precipitate was separated, washed successively with 200mL of acetone for 5 times, and then placed in a vacuum oven and dried under vacuum at 40℃for 24 hours at a vacuum of-0.09 MPa. After complete drying, 0.4g of xerogel is taken, 200mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL is added, after the gel is completely swelled, the gel is filled into a prefilled syringe, and moist heat sterilization is carried out at 121 ℃ for 15min, thus obtaining the final product gel. The gel particle diameter D0.5 was 125. Mu.m, and D0.9 was 201. Mu.m.
Example 12: EDC catalyzes four-site crosslinking of spermine and hyaluronic acid
6g of sodium hyaluronate (molecular weight 120 kDa) was weighed, then 35mL of purified water was added thereto, and after complete dissolution, at this time the concentration of hyaluronic acid was 150mg/mL, 2.1g (molar number: 10.4 mmol) of spermine was added to the hyaluronic acid solution, at this time the content of spermine was 35% of the mass of hyaluronic acid. Under the precondition of four-site crosslinking, the pH value of the hyaluronic acid solution is regulated to about 5.2 by using a hydrochloric acid solution with the concentration of 6mol/L, then the mixture is added and stirred uniformly, 57.2mmol EDC (namely 550% of spermine mole number) is added, meanwhile, 2.0g of HOBt (20% of EDC mass) is added, the mixture is stirred uniformly continuously, and the mixture is sealed and placed into a blast drying oven with the temperature of 60 ℃ for reaction for 24 hours. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. After complete drying, 1.0g of xerogel is taken, 20mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL is added, after the gel is completely swelled, the gel is filled into a prefilled syringe, and moist heat sterilization is carried out at 121 ℃ for 15min, thus obtaining the final product gel. The gel particle diameter D0.5 was 148 μm and D0.9 was 197. Mu.m.
Example 13: preparation of double-site crosslinked hydrogel under HATU catalytic spermidine and hyaluronic acid meta-acid conditions
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.022g (molar number: 0.15 mmol) of spermidine was added to the hyaluronic acid solution, at this time the content of spermidine was 0.7% of the mass of hyaluronic acid (molar number of repeating structural units of hyaluronic acid: 2%). Adding 0.48mmol of HATU, namely 320 percent of spermidine mole number, uniformly stirring, adjusting the pH value of the hyaluronic acid solution to about 4.60 by using a 6mol/L hydrochloric acid solution, then adding and uniformly stirring, and hermetically placing into a 50 ℃ incubator for reaction for 14h. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 138 μm and D0.9 was 210. Mu.m.
Comparative example 1: preparation of HATU-catalyzed spermidine-hyaluronic acid crosslinked hydrogel under strong acid conditions 3.0g of sodium hyaluronate (molecular weight 900kDa, containing 7.4mmol of repeated structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, after complete dissolution, at which time the concentration of hyaluronic acid was 30mg/mL, 0.022g (mole number 0.15 mmol) of spermidine was added to the hyaluronic acid solution, at which time the spermidine content was 0.7% of the mass of hyaluronic acid (mole number of repeated structural units of hyaluronic acid was 2%). Adding 0.48mmol of HATU, namely 320 percent of spermidine mole number, uniformly stirring, adjusting the pH value of the hyaluronic acid solution to about 3.20 by using a 6mol/L hydrochloric acid solution, then adding and uniformly stirring, and sealing and placing into a 50 ℃ incubator for reaction for 14h. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 143. Mu.m, and D0.9 was 201. Mu.m.
Comparative example 2: EDC catalyzes spermine and hyaluronic acid to carry out crosslinking reaction
This comparative example was gel prepared according to the method disclosed in US9907739B 2.
3.0g of sodium hyaluronate (molecular weight: 900kDa, containing 7.4mmol of repeating structural units of hyaluronic acid) was weighed, then 98mL of purified water was added, and after complete dissolution, at this time the concentration of hyaluronic acid was 30mg/mL, 0.03g (mole number: 0.15 mmol) of spermine was added to the hyaluronic acid solution, at this time the spermine content was 1% of the mass of hyaluronic acid (mole number of repeating structural units of hyaluronic acid: 2%). Adjusting the pH value of the hyaluronic acid solution to about 6.2 by using a 6mol/L hydrochloric acid solution, uniformly stirring, adding 7.4mmol EDC (electro-chemical vapor deposition), namely 100% of the mole number of the hyaluronic acid structural unit and 49 times of the mole number of spermine, simultaneously adding HOBt with 20% of the mass of the EDC, continuously stirring uniformly, sealing and placing into a constant temperature box at 25 ℃ for reaction for 24 hours. After the reaction is finished, 40mL of absolute ethyl alcohol is added, and an IKA T25 high shear disperser is adopted to pulverize gel particles, wherein the pulverizing speed is 10000 revolutions per minute, and the duration is 5 minutes. After the completion of the pulverization, 200mL of absolute ethyl alcohol was continuously added to completely dehydrate the gel. Separating the precipitate, continuously cleaning the precipitate with 200mL of absolute ethyl alcohol for 5 times, and vacuum drying the precipitate in a vacuum oven at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours. And after the gel is completely dried, taking 1.0g of xerogel, adding 50mL of pH7.0 phosphate buffer solution with the concentration of 10mg/mL to prepare hydrogel with the concentration of 20mg/mL of hyaluronic acid, filling the gel into a prefilled syringe after the gel is completely swelled, and carrying out damp-heat sterilization at the temperature of 121 ℃ for 15min to obtain the final product gel. The gel particle diameter D0.5 was 155. Mu.m, and D0.9 was 221. Mu.m.
Example 14: spermine or spermidine crosslinking efficiency detection
2.0ml of each of the hyaluronic acid gels obtained in examples 1 to 8 and comparative examples 1 to 2 was taken out, and 50ml of absolute ethanol was added to each gel, and the mixture was stirred for 30 minutes until the gel became a white precipitate. Separating the precipitate, and vacuum drying at 40 ℃ under the vacuum degree of-0.09 MPa for 24 hours to remove ethanol. The gel was taken out, 10mL of sulfuric acid solution of 0.5mol/L was added thereto, and after 2 hours of treatment at 90℃the gel was neutralized to pH=7 with sodium hydroxide solution of 6mol/L, respectively. The solution is placed into a vacuum drying oven, and is dried for 24 hours under the vacuum degree of-0.09 MPa at the temperature of 60 ℃ to remove redundant water. Dissolved in deuterated water at a concentration of 10mg/mL and subjected to 1H spectroscopy by a 400M nuclear magnetic resonance spectrometer.
By aligning 1 The key characteristic peaks in the H NMR spectrum are integrated, the actual molar ratio of spermidine to hyaluronic acid is obtained through integrating the peak areas, and the crosslinking efficiency is obtained through the ratio of the actual molar ratio to the theoretical molar ratio (calculated according to actual feeding). Wherein, the characteristic H atoms selected from spermidine are alpha-H of amino or imino, the number of hydrogen atoms is 8, the characteristic H atoms selected from spermine are alpha-H of amino or imino, the number of H atoms is 12, the integral range of the H atoms of spermine and spermidine is the same, and the integral range of the H atoms of spermine and spermidine is 2.5-2.85ppm; the characteristic H atoms selected from hyaluronic acid are alpha-H of carbonyl in acetamido, wherein the number of H atoms is 3, and the integral range is 1.85-2.05ppm; in the integration, the integrated peak area of carbonyl alpha-H in hyaluronic acid is set to be 3, and thus, the integrated peak area of spermidine or amino and imino alpha-H in spermine can be obtained. The calculation formula is as follows:
Actual molar ratio of spermidine cross-linking = integrated peak area of amino groups and imino groups α -H in spermidine/8;
actual crosslinking molar ratio of spermine = integrated peak area of amino and imino α -H in spermine/12;
crosslinking efficiency= (actual crosslinking molar ratio/theoretical crosslinking molar ratio) ×100%.
The crosslinking efficiencies of examples 1-8 are shown in Table 1, and the nuclear magnetic spectra are shown in FIG. 1:
TABLE 1 actual crosslinking efficiency
Analysis from the data in table 1 found that when double site crosslinking, the crosslinking efficiency was lower than that of multi site crosslinking. When comparing examples 1, 4 and examples 2, 3, 5 for two-site crosslinking, it was found that the efficiency of two-site crosslinking is generally lower than that of multi-site crosslinking, probably due to the combined effects of the three conditions of activator usage, pH and temperature, resulting in lower crosslinking efficiency at two-site crosslinking; in the same multi-site crosslinking, the efficiency of activation by each activator is in the order of: HATU > triphenylphosphine salt > DMTMM > EDC + promoter. Among them, HATU activation efficiency can be as high as approximately 95%, while edc+nhs activation efficiency is only 75%. Under the same conditions, the crosslinking efficiency of spermine and spermidine is close, the efficiency of spermine is slightly lower, and the possibility is caused by higher content of imino groups in spermine, the steric hindrance of the imino groups is larger, and the reactivity is lower than that of primary amino groups. In addition, by analysis of the comparative example, the reactivity of amino groups with imino groups was inhibited outside the multi-site pH range, and thus the crosslinking efficiency was low; at a temperature lower than the test temperature of multi-site crosslinking, even if the reaction is carried out according to the conditions of multi-site crosslinking, the finally obtained crosslinking efficiency is similar to that of double-site crosslinking, and the reaction efficiency is lower.
Example 15: effect of spermidine Cross-Linked hyaluronic acid gel on cell proliferation
L-929 cells were seeded in cell culture medium, and 1% penicillin-streptomycin solution and 10% fetal bovine serum solution were added. L-929 cells were incubated in a humidified 5% carbon dioxide cell incubator at 37℃for 3 days. Then, the spermidine three-site crosslinked hyaluronic acid gel obtained in example 2 was transferred into a 96-well plate, cured by an ultraviolet lamp and sterilized. Again, L-929 cell culture broth was added to wells containing spermidine crosslinked hyaluronic acid gel, and 1mL of trypsin solution containing 0.1% EDTA was added, the number of L-929 cells in each well being 1X 10 5 And each. And continue to be placed in the cell incubator to promote cell growth.
The proliferation rate of spermidine crosslinked hyaluronic acid gel cells was determined by MTT method. After 24, 48 and 72 hours of incubation, 100. Mu.L of MTT aqueous solution (5 mg. Multidot. ML-1) was added to each well and incubation was continued for 4 hours in an incubator. The MTT solution was then removed, 150. Mu.L of dimethylsulfoxide was added to dissolve formazan crystals, and the absorbance of the solution was measured at 490nm wavelength using a microplate reader to determine the extent of cell proliferation of the gel on L-929. Cell viability was calculated according to the following formula:
Cell viability (%) = (As/Ac) ×100%;
where As is the absorbance of the sample solution at 570nm and Ac is the absorbance of the blank at 570 nm.
The cell proliferation results are shown in FIG. 2: from the figure, it can be seen that the cell viability of spermidine cross-linked hyaluronic acid gel at 24, 48 and 72 hours was 112%, 123% and 138%, respectively. From the cell viability of these two types of gels, it can be seen that spermidine crosslinked hyaluronic acid hydrogel has no cytotoxicity, and the phenomenon that the cell viability increases with time indicates that the hydrogel plays a role in promoting cell growth to a certain extent.
Example 16: rheological property detection of spermine or spermidine cross-linked hyaluronic acid gel
Among the hyaluronic acid gels obtained in examples 1 to 13 and comparative example 2, 2.0ml was taken out of each of the two types before sterilization and after sterilization, the elastic modulus (G') of the gel was measured using a TA DHR-2 type flat plate rheometer, and the elastic modulus loss rate was calculated. Wherein the G' loss rate is calculated from the following formula:
g 'loss rate= (pre-sterilization G' -post-sterilization G ')/pre-sterilization G';
rheometer parameters are, operating gap: 1000mm, loading gap: 45000m, operating temperature: 37 ℃, deformation amount: 1%, frequency: 0.9Hz, run time: 60s. The rheological data for each gel are shown in table 2:
TABLE 2 rheological data of gels
The G 'loss rate can be considered as an indicator of the thermal stability of the gel, with lower G' loss rates leading to higher thermal stability of the gel. As can be seen from the data in table 2, taking examples 1-7 as examples, the G' loss rate has a certain relationship with the crosslinking efficiency in example 14, wherein under the condition of similar crosslinking degree and crosslinking efficiency (examples 2 and 3), the thermal stability of the hyaluronic acid crosslinked by spermidine and the hyaluronic acid crosslinked by spermine is similar, but the elastic modulus of spermine is higher and the thermal stability is higher, probably because the crosslinked network structure formed by 4-site crosslinking of spermine is more compact, and the same theory can be applied to the three-site crosslinked spermidine gel and the two-site crosslinked spermidine gel, namely the thermal stability of the two-site crosslinked gel is worse than that of the three-site crosslinked gel. The four activators are compared, and the thermal stability sequence of the gel is as follows: HATU > triphenylphosphine salt > DMTMM > EDC + adjuvant in the same order as in example 14. In addition, the concentration of hyaluronic acid in the crosslinked hyaluronic acid hydrogels also had a large influence on the thermal stability of the gel, and examples 10 and 11 employed the same crosslinking sites as examples 2 and 3, but since the concentrations of hyaluronic acid in the crosslinked hyaluronic acid hydrogels of examples 10 and 11 were 1mg/mL and 2mg/mL, respectively, and the corresponding concentrations of hyaluronic acid in examples 2 and 3 were 20mg/mL, a large difference in G 'was caused, and the decrease value of G' was increased. In addition, the amount of activator added also had a greater effect on the hydrogel properties, and example 1 and example 13 were otherwise identical, with a 28.6% decrease in HATU activator added in example 13 (i.e., 164.8. Mu. Mol) compared to example 1, resulting in a significant decrease in G 'in example 13 compared to example 1 and a significant increase in the G' decrease ratio compared to example 1.
Example 17: release detection of spermidine in gel along with degradation process of hyaluronic acid under thermal degradation condition
Taking 2mL of finished gel in example 2, sealing each sample in a penicillin bottle, placing the sample in a forced air drying oven at 125 ℃ for accelerated hydrolysis, taking out 3 parallel samples every 15min, cooling to about 25 ℃, respectively adjusting the pH to 12 by sodium hydroxide, respectively adding 20mL of chromatographic grade acetone, filtering by a 0.2 mu m filter membrane, and then introducing acetone filtrate into an Agilent 7890B type gas chromatograph, and adopting an SGE H2 capillary column (30 m multiplied by 0.53mm multiplied by 1.0 mu m), wherein the chromatographic conditions are as follows: the temperature of the sample inlet is 220 ℃, the pressure is 40, the separation flow rate is 30, the split ratio is 10:1, the separation time is 0.8, and the column temperature is: 100 ℃ for 0.5min, at 20 ℃/min up to 180 ℃ for 1min, detector (FID): the temperature is 250 ℃, the air flow rate is 350mL/min, the H2 flow rate is 35mL/min, and the tail blowing N2 flow rate is 30mL/min.
The total degradation time is 90min, 6 detection points are set, and the detection result is shown in figure 3.
The purpose of this experiment was to simulate the release of spermidine monomers during thermal degradation of hyaluronic acid due to hydrolysis of the crosslinking sites. However, under normal physiological environment, the degradation process of the crosslinked hyaluronic acid is longer, the period is shorter than several months, and the period is longer than 1 year, so that the experiment adopts the release amount detection experiment of spermidine in the hydrolysis process of spermidine crosslinked hyaluronic acid gel under the high temperature condition higher than 100 ℃, and the degradation process of the hyaluronic acid and the release process of the spermidine can be observed in a shorter time. As shown in fig. 3, the release of spermidine is slow along with the degradation process of hyaluronic acid, the initial release speed is slow, the release speed of spermidine is obviously accelerated along with the disintegration of the crosslinked hyaluronic acid network in the later period, and the accumulated release amount is also obviously improved, so that the release of spermidine in the gel is a slow-first-fast-second process. The experiment can also prove that the crosslinking technology in the invention is an active reaction technology, and can continuously release spermidine monomers in a prototype manner in the continuous degradation process of crosslinked hyaluronic acid, so that the gel can continuously release spermidine in vivo and exert the specific physiological activity of the spermidine.
Example 18: release detection of spermidine in gel with degradation of hyaluronic acid under enzymatic conditions
Taking 2mL of finished gel in example 2, sealing each sample in a penicillin bottle, adding 1000u of hyaluronidase into each sample for accelerated hydrolysis, taking out 3 parallel samples every 30min, cooling to about 25 ℃, taking out 0.5mL of supernatant, respectively adjusting pH to 12 by sodium hydroxide, respectively adding 20mL of chromatographic grade acetone, filtering by using a 0.2 μm filter membrane, and feeding acetone filtrate into an Agilent 7890B type gas chromatograph, and adopting an SGE H2 capillary column (30 m multiplied by 0.53mm multiplied by 1.0 μm), wherein chromatographic conditions are as follows: the temperature of the sample inlet is 220 ℃, the pressure is 40, the separation flow rate is 30, the split ratio is 10:1, the separation time is 0.8, and the column temperature is: 100 ℃ for 0.5min, at 20 ℃/min up to 180 ℃ for 1min, detector (FID): the temperature is 250 ℃, the air flow rate is 350mL/min, the H2 flow rate is 35mL/min, and the tail blowing N2 flow rate is 30mL/min.
The total degradation time is 180min, 6 detection points are set, and the detection result is shown in figure 4.
The purpose of this experiment was to simulate the release of spermidine monomers during enzymatic degradation of hyaluronic acid due to gel degradation. As shown in fig. 4, the release of spermidine is slowly released along with the degradation process of hyaluronic acid, and the release rate of spermidine is almost unchanged in the whole degradation process of hyaluronic acid gel, which indicates that spermidine can be uniformly and stably released when the hyaluronic acid gel obtained by crosslinking with spermidine is enzymatically degraded. The experiment can also prove that the crosslinking technology in the invention is an active reaction technology, and can continuously release spermidine monomers in a prototype manner in the continuous degradation process of crosslinked hyaluronic acid, so that the gel can continuously release spermidine in vivo and exert the specific physiological activity of the spermidine.
Example 19: detection of remaining active sites in double-site and multiple-site cross-linked gels
Taking about 2g of ninhydrin, adding 100ml of purified water to dissolve the ninhydrin, and uniformly mixing the dissolved ninhydrin with the purified water; and (5) keeping the materials away from light at the temperature of 2-8 ℃ for standby. 54.6g of sodium acetate is taken, 20ml of acetic acid solution with the concentration of 1mol/L is added for dissolution, and then water is added for dilution to 500ml for standby. Respectively taking spermidine standard substance and spermine standard substance, placing into a 10ml measuring flask, diluting to scale with purified water, shaking uniformly to prepare 500 μg/ml spermidine standard use solution, and 500ug/ml spermine standard use solution; the standard solution was diluted to 10, 50, 100, 200. Mu.g/ml and used as a standard curve at the time of use.
Taking the hydrogels before wet heat sterilization in examples 1-8 and comparative examples 1 and 2 and the spermine and spermidine series standard solutions, respectively taking 1mL, sequentially adding 2.0mL of the acetic acid-sodium acetate buffer solution and 2.0mL of the ninhydrin solution, adding a plug, fully mixing uniformly, heating in a water bath at 70 ℃ for 30min, taking out, rapidly cooling to room temperature, adding purified water to dilute to 25mL, and uniformly mixing; measuring the absorbance of the amino group derivative at 565nm wavelength of the mixed solution, and simultaneously detecting the absorbance of the amino group derivative at 400nm wavelength; blank correction was performed in the same way with purified water.
The amino or imino residue ratio (%) is calculated as follows:
residual amount ratio= (a 0 -A i )/A 0 ×100％
Wherein A0 is the absorbance value measured by the control solution, and Ai is the absorbance value measured by the sample.
Wherein one spermidine molecule contains one imino group and two amino groups, and one spermine molecule contains two imino groups and two amino groups.
The actual detection results are shown in table 3:
TABLE 3 amino or imino residue ratio in gels
| Examples | Residual amount of amino group | Residual amount of imino groups |
| Example 1 | 10.34％ | 86.61％ |
| Example 2 | 7.31％ | 8.02％ |
| Example 3 | 8.53％ | 9.45％ |
| Examples4 | 18.13％ | 89.45％ |
| Example 5 | 10.16％ | 12.31％ |
| Example 6 | 13.35％ | 13.43％ |
| Example 7 | 17.41％ | 14.31％ |
| Example 8 | 6.32％ | 7.88％ |
| Comparative example 1 | 39.25％ | 97.13％ |
| Comparative example 2 | 40.35％ | 98.31％ |
As is clear from the results of Table 3, examples 1 and 4 were two-site crosslinking, in which the main reactive group was amino group, the reaction efficiency was as high as 89.66% (100% -amino residue, the same applies hereinafter), the lowest amino group reaction efficiency was also more than 80%, and the imino group reaction efficiency was not more than 15%, so that the two-site crosslinking reaction involving the amino group was mainly performed under this condition. In examples 2, 3 and 8, the reaction efficiency of the imino group and the imino group of spermidine or spermine was 90% or more, and in examples 5 to 7, the reaction efficiency of the imino group was 85% or more. Indicating that under this condition, most of spermidine undergoes three-site crosslinking and spermine undergoes four-site crosslinking. The authenticity of the three-site and four-site cross-linking in the present invention was further confirmed. By examination of the comparative example, it was found that the imino reaction efficiency in spermidine or spermine was reduced to not more than 10% and the reaction efficiency of amino groups was also reduced outside the conditions defined in the present invention. Among them, although the total activator of comparative example 2 was added in an amount 49 times that of the crosslinking agent, the imino group in spermine failed to participate in the reaction due to unsuitable reaction conditions such as pH, reaction temperature, etc., and the reaction efficiency of the amino group did not exceed 60%.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (20)
1. A gel material, characterized in that the gel material is obtained by crosslinking endogenous polyamines with hyaluronic acid, wherein the endogenous polyamines comprise spermine and/or spermidine; crosslinking of the endogenous polyamine with the hyaluronic acid comprises two-site crosslinking, three-site crosslinking, or four-site crosslinking;
adjusting the pH=4.50-4.99 or 5.50-6.50 of the mixed solution of hyaluronic acid and endogenous polyamine, adding phosphonium bromide salt formed by carbonium salt and/or triphenylphosphine and bromide serving as activating agents, wherein the temperature of the crosslinking reaction is 10-60 ℃, and the time of the crosslinking reaction is 14-24 hours, so that the hyaluronic acid and the endogenous polyamine are subjected to two-site crosslinking reaction; the amino residue in the gel obtained by the two-site crosslinking is lower than 20%;
Adjusting the pH=5.00-5.49 of a mixed solution of hyaluronic acid and endogenous polyamine, adding phosphonium bromide salt formed by carbonium salt and/or triphenylphosphine serving as an activating agent and bromide, wherein the temperature of the crosslinking reaction is 10-60 ℃, and the time of the crosslinking reaction is 14-24 hours, so that the hyaluronic acid and the endogenous polyamine undergo three-site or four-site crosslinking reaction to obtain the gel material; or alternatively
Adjusting the pH=5.00-5.49 of a mixed solution of hyaluronic acid and endogenous polyamine, adding an activating agent water-soluble carbodiimide and/or 4- (4, 6-dimethoxy triazine-2-yl) -4-methylmorpholine hydrochloride, wherein the temperature of the crosslinking reaction is 40-60 ℃, and the time of the crosslinking reaction is 14-24 hours, so that the hyaluronic acid and the endogenous polyamine undergo three-site or four-site crosslinking reaction to obtain the gel material;
the residual quantity of amino groups and imino groups in the gel obtained by the three-site crosslinking or the four-site crosslinking is lower than 20 percent.
2. The gel material of claim 1, wherein the amino residue in the gel obtained by two-site crosslinking, three-site crosslinking or four-site crosslinking is less than 15%.
3. The gel material of claim 2, wherein the amino residue in the gel obtained by two-site crosslinking, three-site crosslinking or four-site crosslinking is less than 10%.
4. A gel material according to any one of claims 1 to 3 wherein the gel obtained by cross-linking in three-or four-site cross-linking has an imino residue content of less than 15%.
5. The gel material of claim 4, wherein the three-site cross-linking or four-site cross-linking results in a gel having an imino residue content of less than 10%.
6. A gel material according to any one of claims 1 to 3, wherein the crosslinking efficiency of the crosslinking reaction of the endogenous polyamine with hyaluronic acid is higher than 75%.
7. The gel material of claim 6, wherein the crosslinking reaction efficiency of the endogenous polyamine to the hyaluronic acid is greater than 80%.
8. The gel material of claim 7, wherein the crosslinking reaction efficiency of the endogenous polyamine to the hyaluronic acid is greater than 85%.
9. A method of preparing a gel material according to any one of claims 1 to 8, comprising the steps of:
adjusting the pH=4.50-4.99 or 5.50-6.50 of the mixed solution of hyaluronic acid and endogenous polyamine, adding phosphonium bromide salt formed by carbonium salt and/or triphenylphosphine and bromide serving as an activating agent, wherein the temperature of the crosslinking reaction is 10-60 ℃, and the time of the crosslinking reaction is 14-24 hours, so that the hyaluronic acid and the endogenous polyamine undergo a two-site crosslinking reaction to obtain the gel material; or alternatively
Adjusting the pH=5.00-5.49 of a mixed solution of hyaluronic acid and endogenous polyamine, adding phosphonium bromide salt formed by carbonium salt and/or triphenylphosphine serving as an activating agent and bromide, wherein the temperature of the crosslinking reaction is 10-60 ℃, and the time of the crosslinking reaction is 14-24 hours, so that the hyaluronic acid and the endogenous polyamine undergo three-site or four-site crosslinking reaction to obtain the gel material; or alternatively
Adjusting the pH=5.00-5.49 of the mixed solution of hyaluronic acid and endogenous polyamine, adding an activating agent water-soluble carbodiimide and/or 4- (4, 6-dimethoxy triazine-2-yl) -4-methylmorpholine hydrochloride, wherein the temperature of the crosslinking reaction is 40-60 ℃, and the time of the crosslinking reaction is 14-24 hours, so that the hyaluronic acid and the endogenous polyamine undergo three-site or four-site crosslinking reaction, and the gel material is obtained.
10. The method according to claim 9, wherein,
the water-soluble carbodiimide includes one or more of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide, 1- (3-dimethylaminopropyl) -3-ethyl-carbodiimide, 1-cyclohexyl-3- (2-morpholinoethyl) carbodiimide, 1, 3-bis [ bis (methoxymethyl) methyl ] carbodiimide or a salt thereof; the phosphonium bromide salt formed by triphenylphosphine and bromide comprises one or more of phosphonium salt formed by triphenylphosphine and carbon tetrabromide and phosphonium salt formed by triphenylphosphine and N-bromosuccinimide; the carbonium salts include one or more of O- (7-azabenzotriazol-1-yl) -bis (dimethylamino) carbonium hexafluorophosphate, O- (benzotriazol-1-yl) -bis (dimethylamino) carbonium hexafluorophosphate, O- (5-chlorobenzotriazol-1-yl) -bis (dimethylamino) carbonium hexafluorophosphate, O- (benzotriazol-1-yl) -bis (dimethylamino) carbonium tetrafluoroborate, O- (N-succinimidyl) -bis (dimethylamino) carbonium tetrafluoroborate, 2- (5-norbornene-2, 3-dicarboximido) -1, 3-tetramethylurea tetrafluoroborate.
11. The method of claim 9, further comprising, when a water-soluble carbodiimide activator is used, combining with an auxiliary agent; the auxiliary agent comprises any one or more of N-hydroxysuccinimide, sulfonated N-hydroxysuccinimide, tertiary butanol and 1-hydroxybenzotriazole.
12. The method according to claim 9, wherein in the crosslinking reaction, when the two-site crosslinking is performed, the activator is added in an amount of 200 to 280% of the amount of the endogenous polyamine substance;
when three-site and/or four-site crosslinking is performed, the activator is added in an amount of 300 to 550% of the amount of the endogenous polyamine species.
13. The production method according to claim 12, wherein when the endogenous polyamine is spermine, the activator is added in an amount of 400 to 550% of the amount of the spermine substance;
when the endogenous polyamine is spermidine, the addition amount of the activator is 300-400% of the amount of spermidine substance.
14. The method according to claim 9, wherein in the crosslinking reaction, when the endogenous polyamine is spermine, the amount of spermine added is 0.3 to 35% of the mass of the hyaluronic acid; when the endogenous polyamine is spermidine, the adding amount of the spermidine accounts for 0.5-40% of the mass of the hyaluronic acid;
The mass concentration of the hyaluronic acid in the mixed solution is 10-150 mg/mL;
in the finally obtained crosslinked hyaluronic acid hydrogel, the mass concentration of hyaluronic acid is 1-50 mg/mL.
15. The method according to claim 9, wherein the gel material is further subjected to elution with an eluent, pulverization, and drying treatment;
the eluent is an organic solvent;
the volume ratio of gel to eluent in the reaction system is 1:1-5 during crushing;
the particle size of the gel after pulverization is 10-500 μm.
16. The method of claim 15, wherein the organic solvent is a soluble alcohol or a soluble ketone.
17. The method of claim 16, wherein the organic solvent is ethanol or acetone.
18. The method of claim 15, further comprising re-dissolving the dried gel material, and wet heat sterilizing;
the redissolved solution is phosphate buffer solution;
the temperature of the wet heat sterilization is 120-130 ℃, and the time of the wet heat sterilization is 15-45 min.
19. The method according to claim 18, wherein the mass concentration of phosphate buffer salt in the phosphate buffer solution is 5-40 mg/mL.
20. Use of a gel material according to any one of claims 1-8 or a gel material prepared by a method according to any one of claims 9-19 for the preparation of a tissue filling and repair material or a pharmaceutical carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111326226.7A CN113896915B (en) | 2021-11-10 | 2021-11-10 | Gel material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111326226.7A CN113896915B (en) | 2021-11-10 | 2021-11-10 | Gel material and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113896915A CN113896915A (en) | 2022-01-07 |
| CN113896915B true CN113896915B (en) | 2024-02-13 |
Family
ID=79193954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111326226.7A Active CN113896915B (en) | 2021-11-10 | 2021-11-10 | Gel material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113896915B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114712569B (en) * | 2022-04-08 | 2023-06-02 | 中山大学附属第八医院（深圳福田） | Renewable antibacterial bone titanium-based metal material and preparation method and application thereof |
| WO2024040480A1 (en) * | 2022-08-24 | 2024-02-29 | 爱美客技术发展股份有限公司 | Gel material and preparation method therefor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107722140A (en) * | 2017-09-29 | 2018-02-23 | 国家纳米科学中心 | A kind of hyaluronic acid cholesteryl chloroformate polymer and its preparation method and application |
| CN112587723A (en) * | 2020-11-19 | 2021-04-02 | 南京医科大学 | In-situ rapid-forming magnetic hydrogel for repairing urinary system and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2997014B1 (en) * | 2012-10-24 | 2015-03-20 | Teoxane | DERMO-INJECTABLE STERILE COMPOSITION |
| US9421198B2 (en) * | 2013-07-30 | 2016-08-23 | Teoxane | Composition comprising hyaluronic acid and mepivacaine |
-
2021
- 2021-11-10 CN CN202111326226.7A patent/CN113896915B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107722140A (en) * | 2017-09-29 | 2018-02-23 | 国家纳米科学中心 | A kind of hyaluronic acid cholesteryl chloroformate polymer and its preparation method and application |
| CN112587723A (en) * | 2020-11-19 | 2021-04-02 | 南京医科大学 | In-situ rapid-forming magnetic hydrogel for repairing urinary system and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113896915A (en) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113896915B (en) | Gel material and preparation method and application thereof | |
| CN101903408B (en) | Chitosan composition | |
| EP1790665B1 (en) | Process for producing water-soluble modified hyaluronic acid | |
| US8877243B2 (en) | Cross-linked polysaccharide composition | |
| EP2143446B1 (en) | Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same | |
| Dong et al. | Pharmacokinetics and biodegradation mechanisms of a versatile carboxymethyl derivative of chitosan in rats: in vivo and in vitro evaluation | |
| KR101955549B1 (en) | Preparation and/or formulation of proteins cross-linked with polysaccharides | |
| EP1683812B1 (en) | Crosslinked polysaccharide microparticles and method for their preparation | |
| CN104262638B (en) | Hyaluronic acid-cystamine-polylactic acid-glycollic acid graft polymer and preparation method thereof | |
| EP2209814A1 (en) | Dilute filtration sterilization process for viscoelastic biopolymers | |
| US8202986B2 (en) | Branched hyaluronic acid and method of manufacture | |
| EP1564220A1 (en) | Sustained release drug carrier | |
| EP2529226B1 (en) | Silylated biomolecules | |
| CN113929792A (en) | Aldehyde modified hyaluronic acid (sodium) and synthesis method and application thereof | |
| WO2023082084A1 (en) | Gel material, preparation method therefor, and use thereof | |
| CN115054699B (en) | Nanometer drug carrier for liver targeting delivery of miR-26a analogue and preparation method thereof | |
| CN108250462A (en) | A kind of resistance to enzymolysis cross-linking sodium hyaluronate gel and preparation method thereof and preparation | |
| EP2907876B1 (en) | Reduction stimuli-responsive gene vector system and preparation and use thereof | |
| BR112020024654B1 (en) | STERILE HYDROGEL COMPOSITION, APPLICATION UNIT FOR INJECTION, ITS USES, COSMETIC METHOD, SOFT TISSUE FILLING, AND IMPLANT OR DEPOSIT | |
| US11796546B2 (en) | Methods for quantifying drug concentration in a prodrug composition | |
| CN111732675A (en) | Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof | |
| WO2019189073A1 (en) | Hyaluronic acid synthesis promoter, method for promoting hyaluronic acid synthesis, and cell evaluation method | |
| CN112206325B (en) | Long ocular surface retention artificial tear and preparation method thereof | |
| CN117285729A (en) | Humidity-heat-resistant sterilization homogeneous gel and preparation method thereof | |
| CN109925515A (en) | For treating microRNA nano-complex and its preparation and the application of colon cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |